SUPPLEMENT

Q3 2022 — Other Financial Disclosures

Q3 2022PDF · 18 pages767 KB
Table 1: Sales by Segment 1
Table 2: Sales by Geographic Area 2
Table 3: Sales of Key Products/Franchises 3 - 8
Table 3a: Supplemental Sales Reconciliation 9
Table 4: Condensed Consolidated Statement of Earnings - QTD 10
Table 5: Condensed Consolidated Statement of Earnings - YTD 11
Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD 12
Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD 13
Table 8: Non-GAAP Adjusted Net Earnings 14
Table 9: Non-GAAP IBT by Segment - QTD 15
Table 10: Non-GAAP IBT by Segment - YTD 16
Table 11: Non-GAAP P&L Reconciliation 17
Third Quarter 2022
Other Financial Disclosures
Table of Contents

-- 1 of 18 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2022 2021 Total Operations Currency 2022 2021 Total Operations Currency
Sales to customers by
segment of business
Consumer Health (1)
U.S. 1,659	$ 1,625 2.1 % 2.1 - 4,903	$ 4,987 (1.7) % (1.7) -
International 2,136 2,187 (2.3) 6.7 (9.0) 6,283 6,320 (0.6) 6.0 (6.6)
3,795 3,812 (0.4) 4.7 (5.1) 11,186 11,307 (1.1) 2.6 (3.7)
Pharmaceutical (1)
U.S. 7,438 7,221 3.0 3.0 - 21,229 20,536 3.4 3.4 -
International 5,776 5,661 2.0 16.7 (14.7) 18,171 16,927 7.3 18.5 (11.2)
13,214 12,882 2.6 9.0 (6.4) 39,400 37,463 5.2 10.2 (5.0)
Pharmaceutical excluding COVID-19 Vaccine (1,3)
U.S. 7,438 6,951 7.0 7.0 - 21,109 20,115 4.9 4.9 -
International 5,287 5,429 (2.6) 11.3 (13.9) 16,801 16,582 1.3 11.7 (10.4)
12,725 12,380 2.8 8.9 (6.1) 37,910 36,697 3.3 8.0 (4.7)
MedTech (2)
U.S. 3,356 3,117 7.7 7.7 - 9,932 9,470 4.9 4.9 -
International 3,426 3,527 (2.9) 8.5 (11.4) 10,719 10,731 (0.1) 8.2 (8.3)
6,782 6,644 2.1 8.1 (6.0) 20,651 20,201 2.2 6.6 (4.4)
U.S. 12,453 11,963 4.1 4.1 - 36,064 34,993 3.1 3.1 -
International 11,338 11,375 (0.3) 12.3 (12.6) 35,173 33,978 3.5 12.9 (9.4)
Worldwide 23,791 23,338 1.9 8.1 (6.2) 71,237 68,971 3.3 7.9 (4.6)
U.S. 12,453 11,693 6.5 6.5 - 35,944 34,572 4.0 4.0 -
International 10,849 11,143 (2.6) 9.5 (12.1) 33,803 33,633 0.5 9.5 (9.0)
Worldwide excluding COVID-19 Vaccine (3) 23,302	$ 22,836 2.0 % 8.0 (6.0) 69,747	$ 68,205 2.3 % 6.7 (4.4)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.
(3) Refer to supplemental sales reconciliation
Page 1 of 17
THIRD QUARTER
Percent Change
NINE MONTHS
(2) Previously referred to as Medical Devices

-- 2 of 18 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2022 2021 Total Operations Currency 2022 2021 Total Operations Currency
Sales to customers by
geographic area
U.S. 12,453	$ 11,963 4.1 % 4.1 - 36,064	$ 34,993 3.1 % 3.1 -
Europe 5,524 5,587 (1.1) 14.5 (15.6) 17,633 16,669 5.8 18.2 (12.4)
Western Hemisphere excluding U.S. 1,562 1,500 4.1 9.1 (5.0) 4,580 4,291 6.7 9.6 (2.9)
Asia-Pacific, Africa 4,252 4,288 (0.9) 10.5 (11.4) 12,960 13,018 (0.4) 7.2 (7.6)
International 11,338 11,375 (0.3) 12.3 (12.6) 35,173 33,978 3.5 12.9 (9.4)
Worldwide 23,791	$ 23,338 1.9 % 8.1 (6.2) 71,237	$ 68,971 3.3 % 7.9 (4.6)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
Page 2 of 17
THIRD QUARTER
Percent Change
NINE MONTHS

-- 3 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
CONSUMER HEALTH SEGMENT (2,3)
OTC
US 695	$ 686 1.4% 1.4% - 2,028	$ 1,960 3.5% 3.5% -
Intl 825 798 3.4% 12.2% -8.8% 2,434 2,223 9.5% 16.3% -6.8%
WW 1,519 1,484 2.5% 7.2% -4.7% 4,462 4,183 6.7% 10.3% -3.6%
SKIN HEALTH / BEAUTY
US 591 569 3.7% 3.7% - 1,764 1,862 -5.3% -5.3% -
Intl 535 555 -3.6% 6.2% -9.8% 1,500 1,595 -6.0% 1.5% -7.5%
WW 1,126 1,124 0.1% 5.0% -4.9% 3,264 3,457 -5.6% -2.2% -3.4%
ORAL CARE
US 158 150 5.2% 5.2% - 471 478 -1.5% -1.5% -
Intl 217 248 -12.4% -4.3% -8.1% 664 762 -12.8% -7.2% -5.6%
WW 375 398 -5.8% -0.7% -5.1% 1,135 1,240 -8.5% -5.0% -3.5%
BABY CARE
US 91 95 -4.0% -4.0% - 264 288 -8.2% -8.2% -
Intl 283 296 -4.5% 3.4% -7.9% 840 879 -4.4% 0.8% -5.2%
WW 375 391 -4.3% 1.6% -5.9% 1,105 1,167 -5.4% -1.5% -3.9%
WOMEN'S HEALTH
US 2 3 -22.0% -22.0% - 9 9 -2.8% -2.8% -
Intl 222 229 -2.7% 8.4% -11.1% 674 675 -0.1% 8.0% -8.1%
WW 225 232 -3.0% 7.9% -10.9% 684 684 -0.1% 7.8% -7.9%
WOUND CARE / OTHER
US 122 122 -0.2% -0.2% - 366 390 -6.0% -6.0% -
Intl 53 61 -11.4% -7.1% -4.3% 170 186 -8.2% -5.4% -2.8%
WW 176 182 -3.9% -2.5% -1.4% 537 575 -6.7% -5.8% -0.9%
TOTAL CONSUMER HEALTH
US 1,659 1,625 2.1% 2.1% - 4,903 4,987 -1.7% -1.7% -
Intl 2,136 2,187 -2.3% 6.7% -9.0% 6,283 6,320 -0.6% 6.0% -6.6%
WW 3,795	$ 3,812 -0.4% 4.7% -5.1% 11,186	$ 11,307 -1.1% 2.6% -3.7%
See footnotes at end of schedule Page 3 of 17
% Change % Change

-- 4 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
PHARMACEUTICAL SEGMENT (2,3) 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
IMMUNOLOGY
US 2,876	$ 2,771 3.8% 3.8% - 8,230	$ 7,932 3.8% 3.8% -
Intl 1,411 1,480 -4.7% 8.9% -13.6% 4,587 4,464 2.8% 12.9% -10.1%
WW 4,287 4,250 0.9% 5.6% -4.7% 12,817 12,395 3.4% 7.1% -3.7%
REMICADE
US 350 480 -27.0% -27.0% - 1,099 1,508 -27.1% -27.1% -
US Exports (4) 39 47 -16.9% -16.9% - 163 197 -17.2% -17.2% -
Intl 169 234 -27.8% -22.8% -5.0% 606 721 -16.0% -11.9% -4.1%
WW 558 761 -26.6% -25.1% -1.5% 1,868 2,426 -23.0% -21.8% -1.2%
SIMPONI / SIMPONI ARIA
US 298 295 0.9% 0.9% - 886 840 5.4% 5.4% -
Intl 248 276 -10.4% 3.0% -13.4% 797 877 -9.2% 0.4% -9.6%
WW 545 571 -4.6% 1.9% -6.5% 1,682 1,717 -2.0% 2.9% -4.9%
STELARA
US 1,655 1,569 5.5% 5.5% - 4,766 4,396 8.4% 8.4% -
Intl 794 809 -1.9% 12.9% -14.8% 2,571 2,404 6.9% 18.2% -11.3%
WW 2,449 2,378 3.0% 8.0% -5.0% 7,336 6,800 7.9% 11.9% -4.0%
TREMFYA
US 530 376 40.7% 40.7% - 1,303 975 33.6% 33.6% -
Intl 200 161 24.6% 44.5% -19.9% 613 459 33.7% 49.0% -15.3%
WW 729 537 35.9% 41.9% -6.0% 1,916 1,434 33.6% 38.5% -4.9%
OTHER IMMUNOLOGY
US 5 3 * * - 14 15 -3.5% -3.5% -
Intl 0 0 * * * 0 3 * * *
WW 5 3 * * * 14 18 -19.3% -19.3% 0.0%
INFECTIOUS DISEASES
US 390 679 -42.7% -42.7% - 1,266 1,635 -22.6% -22.6% -
Intl 905 698 29.7% 49.1% -19.4% 2,642 1,758 50.3% 67.1% -16.8%
WW 1,295 1,378 -6.0% 3.8% -9.8% 3,908 3,394 15.2% 23.9% -8.7%
COVID-19 VACCINE
US 0 270 * * - 120 421 -71.5% -71.5% -
Intl 489 233 * * * 1,370 346 * * *
WW 489 502 -2.7% 13.1% -15.8% 1,490 766 * * *
EDURANT / rilpivirine
US 9 12 -27.1% -27.1% - 27 31 -14.5% -14.5% -
Intl 237 247 -4.2% 9.8% -14.0% 691 733 -5.7% 4.8% -10.5%
WW 245 259 -5.2% 8.2% -13.4% 718 764 -6.1% 4.0% -10.1%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 372 380 -2.2% -2.2% - 1,096 1,128 -2.9% -2.9% -
Intl 112 137 -17.9% -6.3% -11.6% 354 440 -19.5% -11.2% -8.3%
WW 485 517 -6.4% -3.3% -3.1% 1,450 1,568 -7.5% -5.2% -2.3%
OTHER INFECTIOUS DISEASES
US 10 18 -46.4% -46.4% - 24 55 -57.2% -57.2% -
Intl 68 82 -17.1% -10.8% -6.3% 228 240 -5.0% 0.2% -5.2%
WW 77 99 -22.4% -17.2% -5.2% 251 295 -14.8% -10.6% -4.2%
Page 4 of 17
% Change % Change

-- 5 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
NEUROSCIENCE
US 919 835 10.0% 10.0% - 2,658 2,448 8.6% 8.6% -
Intl 763 845 -9.9% 1.8% -11.7% 2,498 2,751 -9.2% -0.6% -8.6%
WW 1,681 1,680 0.0% 5.9% -5.9% 5,156 5,199 -0.8% 3.7% -4.5%
CONCERTA / Methylphenidate
US 41 35 19.3% 19.3% - 114 117 -2.2% -2.2% -
Intl 117 122 -4.4% 8.0% -12.4% 362 372 -2.6% 6.5% -9.1%
WW 158 157 0.8% 10.5% -9.7% 476 489 -2.5% 4.4% -6.9%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 684 648 5.3% 5.3% - 2,036 1,882 8.1% 8.1% -
Intl 348 355 -2.3% 12.2% -14.5% 1,097 1,111 -1.3% 9.4% -10.7%
WW 1,031 1,004 2.6% 7.8% -5.2% 3,132 2,994 4.6% 8.6% -4.0%
RISPERDAL CONSTA
US 67 71 -6.1% -6.1% - 195 210 -7.1% -7.1% -
Intl 52 69 -24.2% -11.3% -12.9% 178 242 -26.3% -17.0% -9.3%
WW 119 140 -14.9% -8.6% -6.3% 373 452 -17.4% -12.4% -5.0%
OTHER NEUROSCIENCE
US 127 81 57.2% 57.2% - 313 239 31.1% 31.1% -
Intl 246 298 -17.9% -10.0% -7.9% 861 1,026 -16.2% -10.2% -6.0%
WW 374 379 -1.9% 4.3% -6.2% 1,174 1,265 -7.3% -2.4% -4.9%
ONCOLOGY
US 1,812 1,525 18.8% 18.8% - 5,073 4,364 16.2% 16.2% -
Intl 2,252 2,140 5.2% 20.9% -15.7% 6,983 6,406 9.0% 20.8% -11.8%
WW 4,064 3,665 10.9% 20.0% -9.1% 12,056 10,770 11.9% 19.0% -7.1%
DARZALEX
US 1,097 841 30.3% 30.3% - 3,071 2,302 33.4% 33.4% -
Intl 955 739 29.3% 48.2% -18.9% 2,823 2,076 36.0% 50.8% -14.8%
WW 2,052 1,580 29.8% 38.7% -8.9% 5,894 4,378 34.6% 41.6% -7.0%
ERLEADA
US 254 214 19.1% 19.1% - 693 578 20.0% 20.0% -
Intl 235 130 * * * 647 329 * * *
WW 490 344 42.2% 51.2% -9.0% 1,340 907 47.7% 54.9% -7.2%
IMBRUVICA
US 353 413 -14.6% -14.6% - 1,072 1,311 -18.3% -18.3% -
Intl 559 654 -14.6% -2.5% -12.1% 1,847 1,996 -7.5% 1.9% -9.4%
WW 911 1,066 -14.6% -7.2% -7.4% 2,918 3,307 -11.8% -6.1% -5.7%
ZYTIGA / abiraterone acetate
US 16 25 -33.1% -33.1% - 54 96 -43.4% -43.4% -
Intl 440 523 -15.9% -1.2% -14.7% 1,446 1,653 -12.5% -1.9% -10.6%
WW 456 548 -16.7% -2.6% -14.1% 1,500 1,749 -14.2% -4.2% -10.0%
OTHER ONCOLOGY
US 92 32 * * - 183 76 * * -
Intl 64 94 -32.1% -22.6% -9.5% 220 352 -37.5% -31.2% -6.3%
WW 155 126 23.1% 30.2% -7.1% 403 428 -5.9% -0.8% -5.1%
Page 5 of 17
% Change % Change

-- 6 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 604 610 -1.1% -1.1% - 1,736 1,778 -2.4% -2.4% -
Intl 247 258 -3.8% 12.5% -16.3% 810 821 -1.3% 10.5% -11.8%
WW 852 868 -1.9% 3.0% -4.9% 2,547 2,599 -2.0% 1.7% -3.7%
OPSUMIT
US 289 299 -3.4% -3.4% - 827 861 -4.0% -4.0% -
Intl 152 159 -4.7% 11.6% -16.3% 495 510 -3.0% 8.7% -11.7%
WW 441 458 -3.9% 1.8% -5.7% 1,322 1,371 -3.6% 0.7% -4.3%
UPTRAVI
US 283 265 6.6% 6.6% - 824 792 3.9% 3.9% -
Intl 50 44 14.2% 29.5% -15.3% 162 135 20.4% 32.1% -11.7%
WW 333 309 7.7% 9.9% -2.2% 986 927 6.3% 8.0% -1.7%
OTHER PULMONARY HYPERTENSION
US 33 47 -29.5% -29.5% - 86 125 -31.3% -31.3% -
Intl 46 54 -15.7% 1.2% -16.9% 154 176 -13.0% -1.0% -12.0%
WW 78 101 -22.1% -12.9% -9.2% 239 301 -20.5% -13.5% -7.0%
CARDIOVASCULAR / METABOLISM / OTHER
US 837 800 4.5% 4.5% - 2,266 2,379 -4.8% -4.8% -
Intl 198 241 -17.5% -8.8% -8.7% 651 727 -10.4% -3.8% -6.6%
WW 1,034 1,041 -0.6% 1.4% -2.0% 2,916 3,106 -6.1% -4.5% -1.6%
XARELTO
US 689 636 8.4% 8.4% - 1,806 1,794 0.7% 0.7% -
Intl - - - - - - - - - -
WW 689 636 8.4% 8.4% - 1,806 1,794 0.7% 0.7% -
INVOKANA / INVOKAMET
US 49 66 -25.8% -25.8% - 164 249 -34.1% -34.1% -
Intl 60 67 -11.0% -2.5% -8.5% 193 194 -0.6% 6.1% -6.7%
WW 109 133 -18.4% -14.1% -4.3% 357 443 -19.5% -16.6% -2.9%
OTHER
US 98 98 -0.1% -0.1% - 295 336 -12.2% -12.2% -
Intl 138 173 -20.0% -11.3% -8.7% 458 533 -14.0% -7.3% -6.7%
WW 236 271 -12.8% -7.3% -5.5% 753 869 -13.3% -9.2% -4.1%
TOTAL PHARMACEUTICAL
US 7,438 7,221 3.0% 3.0% - 21,229 20,536 3.4% 3.4% -
Intl 5,776 5,661 2.0% 16.7% -14.7% 18,171 16,927 7.3% 18.5% -11.2%
WW 13,214	$ 12,882 2.6% 9.0% -6.4% 39,400	$ 37,463 5.2% 10.2% -5.0%
See footnotes at end of schedule Page 6 of 17
% Change % Change

-- 7 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
MEDTECH SEGMENT (2,3,5) 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 547	$ 444 23.2% 23.2% - 1,566 1,353 15.7% 15.7% -
Intl 513 513 0.0% 13.0% -13.0% 1,636 1,599 2.3% 11.1% -8.8%
WW 1,060 957 10.8% 17.7% -6.9% 3,202 2,952 8.5% 13.2% -4.7%
ORTHOPAEDICS
US 1,309 1,249 4.8% 4.8% - 3,936 3,821 3.0% 3.0% -
Intl 785 843 -6.9% 4.6% -11.5% 2,504 2,611 -4.1% 4.3% -8.4%
WW 2,095 2,093 0.1% 4.7% -4.6% 6,440 6,433 0.1% 3.5% -3.4%
HIPS
US 228 209 9.1% 9.1% - 693 651 6.5% 6.5% -
Intl 124 146 -15.1% -4.5% -10.6% 437 451 -3.3% 4.6% -7.9%
WW 352 355 -0.9% 3.5% -4.4% 1,129 1,102 2.5% 5.7% -3.2%
KNEES
US 203 184 9.8% 9.8% - 620 579 6.9% 6.9% -
Intl 115 131 -12.8% -2.1% -10.7% 386 403 -4.4% 3.7% -8.1%
WW 317 316 0.4% 4.9% -4.5% 1,005 983 2.3% 5.6% -3.3%
TRAUMA
US 473 455 3.8% 3.8% - 1,412 1,352 4.4% 4.4% -
Intl 244 260 -6.0% 6.5% -12.5% 749 805 -7.0% 2.3% -9.3%
WW 717 715 0.2% 4.8% -4.6% 2,161 2,157 0.2% 3.6% -3.4%
SPINE, SPORTS & OTHER
US 406 401 1.3% 1.3% - 1,211 1,239 -2.2% -2.2% -
Intl 303 306 -1.1% 10.2% -11.3% 933 952 -2.0% 6.1% -8.1%
WW 708 706 0.3% 5.2% -4.9% 2,144 2,190 -2.1% 1.4% -3.5%
Page 7 of 17
% Change % Change

-- 8 of 18 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
SURGERY
US 984 948 3.7% 3.7% - 2,897 2,881 0.5% 0.5% -
Intl 1,439 1,457 -1.2% 9.3% -10.5% 4,410 4,418 -0.2% 7.3% -7.5%
WW 2,422 2,405 0.7% 7.1% -6.4% 7,306 7,299 0.1% 4.6% -4.5%
ADVANCED
US 457 440 3.8% 3.8% - 1,328 1,304 1.8% 1.8% -
Intl 701 705 -0.4% 9.8% -10.2% 2,132 2,126 0.3% 7.2% -6.9%
WW 1,158 1,144 1.2% 7.5% -6.3% 3,460 3,430 0.9% 5.2% -4.3%
GENERAL
US 527 508 3.6% 3.6% - 1,569 1,577 -0.5% -0.5% -
Intl 737 752 -2.0% 8.8% -10.8% 2,277 2,292 -0.6% 7.3% -7.9%
WW 1,264 1,261 0.3% 6.7% -6.4% 3,846 3,869 -0.6% 4.1% -4.7%
VISION
US 517 475 8.8% 8.8% - 1,534 1,414 8.5% 8.5% -
Intl 689 714 -3.5% 8.4% -11.9% 2,170 2,103 3.2% 12.9% -9.7%
WW 1,206 1,189 1.4% 8.6% -7.2% 3,704 3,517 5.3% 11.1% -5.8%
CONTACT LENSES / OTHER
US 405 359 12.6% 12.6% - 1,179 1,082 9.0% 9.0% -
Intl 503 522 -3.6% 9.5% -13.1% 1,533 1,525 0.5% 11.1% -10.6%
WW 908 882 3.0% 10.8% -7.8% 2,712 2,607 4.0% 10.2% -6.2%
SURGICAL
US 112 117 -3.2% -3.2% - 355 333 6.8% 6.8% -
Intl 186 191 -3.3% 5.6% -8.9% 637 577 10.3% 17.6% -7.3%
WW 298 308 -3.2% 2.3% -5.5% 992 910 9.0% 13.6% -4.6%
TOTAL MEDTECH
US 3,356 3,117 7.7% 7.7% - 9,932 9,470 4.9% 4.9% -
Intl 3,426 3,527 -2.9% 8.5% -11.4% 10,719 10,731 -0.1% 8.2% -8.3%
WW 6,782	$ 6,644 2.1% 8.1% -6.0% 20,651	$ 20,201 2.2% 6.6% -4.4%
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
(5) Previously referred to as Medical Devices Page 8 of 17
% Change % Change

-- 9 of 18 --

2022 2021 Total Operations Currency 2022 2021 Total Operations Currency
Pharmaceutical
U.S. 7,438	$ 7,221 3.0 % 3.0 - 21,229	$ 20,536 3.4 % 3.4 -
International 5,776 5,661 2.0 16.7 (14.7) 18,171 16,927 7.3 18.5 (11.2)
Worldwide 13,214 12,882 2.6 9.0 (6.4) 39,400 37,463 5.2 10.2 (5.0)
COVID-19 Vaccine
U.S. 0 270 * * - 120 421 (71.5) (71.5) -
International 489 233 * * * 1,370 346 * * *
Worldwide 489 502 (2.7) 13.1 (15.8) 1,490 766 * * *
Pharmaceutical excluding COVID-19 Vaccine
U.S. 7,438 6,951 7.0 7.0 - 21,109 20,115 4.9 4.9 -
International 5,287 5,429 (2.6) 11.3 (13.9) 16,801 16,582 1.3 11.7 (10.4)
Worldwide 12,725 12,380 2.8 8.9 (6.1) 37,910 36,697 3.3 8.0 (4.7)
Worldwide
U.S. 12,453 11,963 4.1 4.1 - 36,064 34,993 3.1 3.1 -
International 11,338 11,375 (0.3) 12.3 (12.6) 35,173 33,978 3.5 12.9 (9.4)
Worldwide 23,791 23,338 1.9 8.1 (6.2) 71,237 68,971 3.3 7.9 (4.6)
COVID-19 Vaccine
U.S. 0 270 * * - 120 421 (71.5) (71.5) -
International 489 233 * * * 1,370 346 * * *
Worldwide 489 502 (2.7) 13.1 (15.8) 1,490 766 * * *
Worldwide
U.S. 12,453 11,693 6.5 6.5 - 35,944 34,572 4.0 4.0 -
International 10,849 11,143 (2.6) 9.5 (12.1) 33,803 33,633 0.5 9.5 (9.0)
Worldwide excluding COVID-19 Vaccine 23,302	$ 22,836 2.0 % 8.0 (6.0) 69,747	$ 68,205 2.3 % 6.7 (4.4)
Note: Columns and rows within tables may not add due to rounding
* Percentage greater than 100% or not meaningful
Page 9 of 17
Supplemental Sales Reconciliation (Unaudited)
(Dollars in Millions)
THIRD QUARTER NINE MONTHS
Percent Change Percent Change

-- 10 of 18 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 23,791	$ 100.0 23,338	$ 100.0 1.9
Cost of products sold 7,807 32.8 7,250 31.1 7.7
Gross Profit 15,984 67.2 16,088 68.9 (0.6)
Selling, marketing and administrative expenses 6,089 25.6 6,000 25.7 1.5
Research and development expense 3,597 15.1 3,422 14.7 5.1
In-process research and development - - 900 3.9
Interest (income) expense, net (99) (0.4) 7 0.0
Other (income) expense, net 493 2.1 1,850 7.9
Restructuring 82 0.3 60 0.2
Earnings before provision for taxes on income 5,822 24.5 3,849 16.5 51.3
Provision for taxes on income 1,364 5.8 182 0.8 649.5
Net earnings 4,458	$ 18.7 3,667	$ 15.7 21.6
Net earnings per share (Diluted) 1.68	$ 1.37	$ 22.6
Average shares outstanding (Diluted) 2,661.3 2,674.9
Effective tax rate 23.4 % 4.7 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 8,073	$ 33.9 8,058	$ 34.5 0.2
Net earnings 6,779	$ 28.5 6,968	$ 29.9 (2.7)
Net earnings per share (Diluted) 2.55	$ 2.60	$ (1.9)
Effective tax rate 16.0 % 13.5 %
(1) See Reconciliation of Non-GAAP Financial Measures.
Page 10 of 17
THIRD QUARTER
2022 2021

-- 11 of 18 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 71,237	$ 100.0 68,971	$ 100.0 3.3
Cost of products sold 23,324 32.7 21,900 31.8 6.5
Gross Profit 47,913 67.3 47,071 68.2 1.8
Selling, marketing and administrative expenses 18,253 25.7 17,505 25.4 4.3
Research and development expense 10,762 15.1 9,994 14.5 7.7
In-process research and development 610 0.9 900 1.3
Interest (income) expense, net (137) (0.2) 83 0.1
Other (income) expense, net 664 0.9 480 0.7
Restructuring 237 0.3 169 0.2
Earnings before provision for taxes on income 17,524 24.6 17,940 26.0 (2.3)
Provision for taxes on income 3,103 4.4 1,798 2.6 72.6
Net earnings 14,421	$ 20.2 16,142	$ 23.4 (10.7)
Net earnings per share (Diluted) 5.41	$ 6.04	$ (10.4)
Average shares outstanding (Diluted) 2,667.5 2,674.6
Effective tax rate 17.7 % 10.0 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 24,462	$ 34.3 24,125	$ 35.0 1.4
Net earnings 20,820	$ 29.2 20,517	$ 29.7 1.5
Net earnings per share (Diluted) 7.81	$ 7.67	$ 1.8
Effective tax rate 14.9 % 15.0 %
(1) See Reconciliation of Non-GAAP Financial Measures.
Page 11 of 17
NINE MONTHS
2022 2021

-- 12 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health Pharmaceutical MedTech Total
WW As Reported (0.4)% 2.6% 2.1% 1.9%
U.S. 2.1% 3.0% 7.7% 4.1%
International (2.3)% 2.0% (2.9)% (0.3)%
WW Currency (5.1) (6.4) (6.0) (6.2)
U.S. - - - -
International (9.0) (14.7) (11.4) (12.6)
WW Operational 4.7% 9.0% 8.1% 8.1%
U.S. 2.1% 3.0% 7.7% 4.1%
International 6.7% 16.7% 8.5% 12.3%
All Other Acquisitions and Divestitures 0.1 0.2 0.0 0.1
U.S. 0.2 0.2 (0.2) 0.1
International 0.0 0.1 0.2 0.1
WW Adjusted Operational 4.8% 9.2% 8.1% 8.2%
U.S. 2.3% 3.2% 7.5% 4.2%
International 6.7% 16.8% 8.7% 12.4%
Page 12 of 17
Adjusted Operational Sales Growth
THIRD QUARTER 2022 ACTUAL vs. 2021 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum.

-- 13 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health Pharmaceutical MedTech Total
WW As Reported (1.1)% 5.2% 2.2% 3.3%
U.S. (1.7)% 3.4% 4.9% 3.1%
International (0.6)% 7.3% (0.1)% 3.5%
WW Currency (3.7) (5.0) (4.4) (4.6)
U.S. - - - -
International (6.6) (11.2) (8.3) (9.4)
WW Operational 2.6% 10.2% 6.6% 7.9%
U.S. (1.7)% 3.4% 4.9% 3.1%
International 6.0% 18.5% 8.2% 12.9%
All Other Acquisitions and Divestitures 0.5 0.1 0.1 0.2
U.S. 0.2 0.1 (0.2) 0.1
International 0.7 0.1 0.2 0.2
WW Adjusted Operational 3.1% 10.3% 6.7% 8.1%
U.S. (1.5)% 3.5% 4.7% 3.2%
International 6.7% 18.6% 8.4% 13.1%
Page 13 of 17
Adjusted Operational Sales Growth
NINE MONTHS 2022 ACTUAL vs. 2021 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum.

-- 14 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2022 2021 2022 2021
Net Earnings, after tax- as reported $4,458 $3,667 $14,421 $16,142
Pre-tax Adjustments
Intangible Asset Amortization expense 1,041 1,159 3,244 3,576
Litigation related 219 2,077 604 2,054
IPR&D - 900 610 900
Restructuring related 123 121 323 333
Acquisition, integration and divestiture related ¹ - 20 - (504)
(Gains)/losses on securities 164 (127) 684 (335)
Medical Device Regulation 2 78 59 208 161
COVID-19 Vaccine related costs 3 377 - 653 -
Consumer Health separation costs 249 - 619 -
Other - - (7) -
Tax Adjustments
Tax impact on special item adjustments 4 (379) (849) (1,085) (1,097)
Consumer Health separation tax related costs 361 - 459 -
Tax legislation and other tax related 88 (59) 87 (713)
Adjusted Net Earnings, after tax $6,779 $6,968 $20,820 $20,517
Average shares outstanding (Diluted) 2,661.3 2,674.9 2,667.5 2,674.6
Adjusted net earnings per share (Diluted) $2.55 $2.60 $7.81 $7.67
Operational adjusted net earnings per share (Diluted) $2.75 $8.25
Notes:
1
2
3
4
Page 14 of 17
Nine Months Ended
Acquisition, integration and divestiture related for the nine months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing
European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May
2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded
only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing
performance which is expected to be completed during 2024.
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses,
associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all customer contractual requirements.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted
earnings.
Third Quarter

-- 15 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021
Reported Income Before Tax by Segment $ 809 (577) 4,249 4,200 1,124 423 (111) (197) (249) - 5,822 3,849
% to Sales 21.3% -15.1% 32.2% 32.6% 16.6% 6.4% -0.5% -0.8% -1.0% 0.0% 24.5% 16.5%
Intangible asset amortization expense 83 103 698 799 260 257 - - - - 1,041 1,159
In-process research and development - - - 900 - - - - - 900
Litigation related - 1,359 7 756 212 (38) - - - - 219 2,077
Loss/(gain) on securities - 1 177 (135) (13) 7 - - - - 164 (127)
Restructuring related 31 36 23 17 69 68 - - - - 123 121
Acquisition, integration and divestiture related - - - 3 - 17 - - - - - 20
Medical Device Regulation - - - - 78 59 - - - - 78 59
COVID-19 Vaccine related costs - - 377 - - - - - - - 377 -
Consumer Health separation costs - - - - - - - - 249 - 249 -
Other - - - - - - - - - - - -
Adjusted Income Before Tax by Segment $ 923 922 5,531 5,640 1,730 1,693 (111) (197) - - 8,073 8,058
% to Sales 24.3% 24.2% 41.9% 43.8% 25.5% 25.5% -0.5% -0.8% 0.0% 0.0% 33.9% 34.5%
1 Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
*Estimated as of 10/18/2022
Page 15 of 17
Q3 QTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health
Separation Costs	Consumer Health1 Pharmaceutical1 MedTech Unallocated Worldwide Total

-- 16 of 18 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021
Reported Income Before Tax by Segment $ 2,279 1,131 12,593 13,663 3,742 3,798 (471) (652) (619) - 17,524 17,940
% to Sales 20.4% 10.0% 32.0% 36.5% 18.1% 18.8% -0.7% -0.9% -0.9% 0.0% 24.6% 26.0%
Intangible asset amortization expense 277 314 2,194 2,497 773 765 - - - - 3,244 3,576
In-process research and development - - 610 - - 900 - - - - 610 900
Litigation related 78 1,481 43 675 483 (102) - - - - 604 2,054
Loss/(gain) on securities - (19) 673 (249) 11 (67) - - - - 684 (335)
Restructuring related 70 91 32 54 221 188 - - - - 323 333
Acquisition, integration and divestiture related - - - (567) - 63 - - - - - (504)
Medical Device Regulation - - - - 208 161 - - - - 208 161
COVID-19 Vaccine related costs - - 653 - - - - - - - 653 -
Consumer Health separation costs - - - - - - - - 619 - 619 -
Other - - - - - - (7) - - - (7) -
Adjusted Income Before Tax by Segment $ 2,704 2,998 16,798 16,073 5,438 5,706 (478) (652) - - 24,462 24,125
% to Sales 24.2% 26.5% 42.6% 42.9% 26.3% 28.2% -0.7% -0.9% 0.0% 0.0% 34.3% 35.0%
1 Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
*Estimated as of 10/18/2022
Page 16 of 17
Q3 YTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health
Separation Costs	Consumer Health1 Pharmaceutical1 MedTech Unallocated Worldwide Total

-- 17 of 18 --

Third Quarter Third Quarter
Oct 2, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation Other
Oct 2, 2022
Non-GAAP
Cost of products sold 7,807	$ (1,041) (13) (29) (102) - - - - 6,622
Selling, marketing and admin expenses 6,089 (7) (2) 6,080
Research and development expense 3,597 - (42) (80) - 3,475
Other (Income) / Expense 493 - (219) (28) - (164) (195) (247) - - (360)
In-process research and development - - -
Restructuring 82 (82) -
Provision for taxes on income 1,364 164 (7) - 23 - 43 15 96 45 (361) (88) - 1,294
Net Earnings 4,458 877 226 - 100 - 121 63 281 204 361 88 - 6,779
Third Quarter Third Quarter
Oct 3, 2021
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation Other
Oct 3, 2021
Non-GAAP
Cost of products sold 7,250	$ (1,133) (18) (22) 6,077
Selling, marketing and admin expenses 6,000 (6) 5,994
Research and development expense 3,422 - (31) 3,391
Other (Income) / Expense 1,850 (26) (2,077) (43) (20) 127 - - - - (189)
In-process research and development 900 (900) -
Restructuring 60 (60) -
Provision for taxes on income 182 165 433 202 22 (6) 22 11 - - - 59 - 1,090
Net Earnings 3,667 994 1,644 698 99 26 (149) 48 - - - (59) - 6,968
Nine Months Nine Months
Oct 2, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation Other
Oct 2, 2022
Non-GAAP
Cost of products sold 23,324	$ (3,232) (46) (76) (296) 19,674
Selling, marketing and admin expenses 18,253 (19) (2) 18,232
Research and development expense 10,762 - (113) (190) 10,459
Other (Income) / Expense 664 (12) (604) (40) - (684) (167) (617) - 7 (1,453)
In-process research and development 610 (610) -
Restructuring 237 (237) -
Provision for taxes on income 3,103 502 (89) 138 60 - 164 39 161 112 (459) (87) (2) 3,642
Net Earnings 14,421 2,742 693 472 263 - 520 169 492 507 459 87 (5) 20,820
Nine Months Nine Months
Oct 3, 2021
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation Other
Oct 3, 2021
Non-GAAP
Cost of products sold 21,900	$ (3,550) (65) (59) 18,226
Selling, marketing and admin expenses 17,505 (17) 17,488
Research and development expense 9,994 - (85) 9,909
Other (Income) / Expense 480 (26) (2,054) (99) 504 335 - - - - (860)
In-process research and development 900 (900) -
Restructuring 169 (169) -
Provision for taxes on income 1,798 505 432 202 59 (104) (27) 30 - - - 713 - 3,608
Net Earnings 16,142 3,071 1,622 698 274 (400) (308) 131 - - - (713) - 20,517
(1) 2021 primarily includes gains on the divestitures of two Pharmaceutical brands outside of the United States.
Page 17 of 17
Tax legislation
and other tax
related
Consumer Health
separation tax
related costs
In-process
research and
development
Acquisition, integration and
divestiture related (1)
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation costs
Tax legislation
and other tax
related
Consumer Health
separation tax
related costs
In-process
research and
development
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation costs
Consumer Health
separation tax
related costs
Acquisition, integration and
divestiture related
Consumer Health
separation costs
Tax legislation
and other tax
related
Year to Date
In-process
research and
development
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
Consumer Health
separation tax
related costs
Acquisition, integration and
divestiture related
Consumer Health
separation costs
Tax legislation
and other tax
related
In-process
research and
development
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs

-- 18 of 18 --